FY2025 Earnings Forecast for Bruker Issued By Zacks Research

Bruker Co. (NASDAQ:BRKR) – Research analysts at Zacks Research dropped their FY2025 earnings estimates for shares of Bruker in a research report issued on Monday, February 10th. Zacks Research analyst R. Department now anticipates that the medical research company will earn $2.73 per share for the year, down from their previous estimate of $2.76. The consensus estimate for Bruker’s current full-year earnings is $2.40 per share. Zacks Research also issued estimates for Bruker’s Q4 2025 earnings at $0.92 EPS, Q4 2026 earnings at $0.84 EPS and FY2026 earnings at $3.32 EPS.

Several other equities analysts have also recently weighed in on BRKR. Bank of America increased their price target on Bruker from $78.00 to $80.00 and gave the company a “buy” rating in a report on Friday, December 13th. TD Cowen dropped their target price on Bruker from $72.00 to $70.00 and set a “hold” rating on the stock in a research report on Wednesday, November 6th. The Goldman Sachs Group upgraded Bruker from a “sell” rating to a “neutral” rating and set a $60.00 price target for the company in a research note on Thursday, December 5th. Barclays lowered their price objective on shares of Bruker from $69.00 to $65.00 and set an “overweight” rating on the stock in a research note on Monday. Finally, UBS Group began coverage on shares of Bruker in a report on Tuesday, December 10th. They set a “neutral” rating and a $66.00 target price for the company. Six investment analysts have rated the stock with a hold rating and seven have assigned a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $74.09.

Bruker Stock Down 0.9 %

BRKR opened at $50.65 on Wednesday. Bruker has a twelve month low of $48.07 and a twelve month high of $94.86. The company has a quick ratio of 0.73, a current ratio of 1.66 and a debt-to-equity ratio of 1.24. The firm has a 50 day moving average price of $58.04 and a 200-day moving average price of $60.84. The stock has a market capitalization of $7.68 billion, a price-to-earnings ratio of 24.35, a PEG ratio of 3.81 and a beta of 1.16.

Hedge Funds Weigh In On Bruker

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. True Wealth Design LLC raised its holdings in shares of Bruker by 4,636.4% during the 3rd quarter. True Wealth Design LLC now owns 521 shares of the medical research company’s stock worth $36,000 after acquiring an additional 510 shares in the last quarter. UMB Bank n.a. raised its stake in Bruker by 115.3% during the third quarter. UMB Bank n.a. now owns 661 shares of the medical research company’s stock valued at $46,000 after purchasing an additional 354 shares in the last quarter. Eagle Bay Advisors LLC lifted its position in Bruker by 2,324.1% during the fourth quarter. Eagle Bay Advisors LLC now owns 703 shares of the medical research company’s stock valued at $41,000 after purchasing an additional 674 shares during the last quarter. GAMMA Investing LLC lifted its position in Bruker by 81.0% during the third quarter. GAMMA Investing LLC now owns 867 shares of the medical research company’s stock valued at $60,000 after purchasing an additional 388 shares during the last quarter. Finally, Values First Advisors Inc. purchased a new position in shares of Bruker in the 3rd quarter worth $73,000. 79.52% of the stock is owned by institutional investors.

Insiders Place Their Bets

In other news, CEO Frank H. Laukien acquired 100,000 shares of the business’s stock in a transaction dated Monday, November 18th. The stock was purchased at an average price of $50.14 per share, for a total transaction of $5,014,000.00. Following the completion of the transaction, the chief executive officer now directly owns 38,439,563 shares in the company, valued at approximately $1,927,359,688.82. This trade represents a 0.26 % increase in their position. The acquisition was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. 28.30% of the stock is currently owned by corporate insiders.

Bruker Dividend Announcement

The firm also recently declared a quarterly dividend, which was paid on Monday, December 16th. Investors of record on Monday, December 2nd were issued a $0.05 dividend. The ex-dividend date of this dividend was Monday, December 2nd. This represents a $0.20 dividend on an annualized basis and a yield of 0.39%. Bruker’s dividend payout ratio is presently 9.62%.

Bruker Company Profile

Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies.